{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(13)"],"submitter":["Rao J"],"pubmed_abstract":["Primary liver cancer (PLC) is a primary cause of cancer-related death worldwide, and novel treatments are needed due to the limited options available for treatment and tumor heterogeneity. 66 surgically removed PLC samples were cultured using the self-developed 2:2 method, and the final success rate for organoid culture was 40.9%. Organoid performance has been evaluated using comprehensive molecular measurements, such as whole-exome and RNA sequencing, as well as anticancer drug testing. Multiple organoids and their corresponding tumor tissues contained several of the same mutations, with all pairs sharing conventional TP53 mutations. Regarding copy number variations and gene expression, significant correlations were observed between the organoids and their corresponding parental tumor tis"],"journal":["International journal of biological sciences"],"pagination":["5363-5374"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11488587"],"repository":["biostudies-literature"],"pubmed_title":["Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment."],"pmcid":["PMC11488587"],"pubmed_authors":["Li J","Cheng F","Fan Y","Ren Y","Song C","Gu Z","Hao Y","Xuan Z","Li W","Chen Z","Xu S","Rao J","Feng S","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment.","description":"Primary liver cancer (PLC) is a primary cause of cancer-related death worldwide, and novel treatments are needed due to the limited options available for treatment and tumor heterogeneity. 66 surgically removed PLC samples were cultured using the self-developed 2:2 method, and the final success rate for organoid culture was 40.9%. Organoid performance has been evaluated using comprehensive molecular measurements, such as whole-exome and RNA sequencing, as well as anticancer drug testing. Multiple organoids and their corresponding tumor tissues contained several of the same mutations, with all pairs sharing conventional TP53 mutations. Regarding copy number variations and gene expression, significant correlations were observed between the organoids and their corresponding parental tumor tis","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T00:45:46.173Z","creation":"2025-04-04T00:45:46.173Z"},"accession":"S-EPMC11488587","cross_references":{"pubmed":["39430248"],"doi":["10.7150/ijbs.96317"]}}